Latest & greatest articles for isosorbide mononitrate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on isosorbide mononitrate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on isosorbide mononitrate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for isosorbide mononitrate

1. Isosorbide mononitrate

Isosorbide mononitrate Top results for isosorbide mononitrate - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top (...) search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for isosorbide mononitrate The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection

Trip Latest and Greatest2018

2. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction.

Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. BACKGROUND: Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. We compared the effect of isosorbide mononitrate or placebo on daily activity in such patients. METHODS: In this multicenter, double-blind, crossover study, 110 patients with heart failure and a preserved ejection fraction were randomly assigned to a 6-week dose-escalation regimen (...) of isosorbide mononitrate (from 30 mg to 60 mg to 120 mg once daily) or placebo, with subsequent crossover to the other group for 6 weeks. The primary end point was the daily activity level, quantified as the average daily accelerometer units during the 120-mg phase, as assessed by patient-worn accelerometers. Secondary end points included hours of activity per day during the 120-mg phase, daily accelerometer units during all three dose regimens, quality-of-life scores, 6-minute walk distance, and levels

NEJM2015

3. Oral misoprostol and vaginal isosorbide mononitrate for labor induction: a randomized controlled trial

Oral misoprostol and vaginal isosorbide mononitrate for labor induction: a randomized controlled trial 20567177 2010 06 22 2010 11 15 2016 11 25 1873-233X 116 1 2010 Jul Obstetrics and gynecology Obstet Gynecol Oral misoprostol and vaginal isosorbide mononitrate for labor induction: a randomized controlled trial. 121-6 10.1097/AOG.0b013e3181e408f2 To estimate whether vaginal isosorbide mononitrate, added to oral misoprostol for cervical ripening and labor induction, shortens time to vaginal (...) delivery. A prospective, randomized trial was conducted. Women scheduled for labor induction between 32 and 42 weeks and with unfavorable cervices (modified Bishop score 6 or lower) were randomized to receive oral misoprostol every 4 hours, up to four doses, with or without isosorbide mononitrate every 6 hours, up to two doses. A strict protocol was used, including timing of oxytocin use and amniotomy. Side effects were assessed 6 hours after study initiation. One hundred forty-two patients were

EvidenceUpdates2010

4. Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices

Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices Gluud LL, Langholz E, Krag A CRD summary This review reported that isosorbide (...) mononitrate alone or in combination with beta blockers did not appear to reduce bleeding in primary or secondary prevention of oesophageal varices. Survival may have increased in comparison with endoscopic therapy. Further research was required. These cautious conclusions and recommendations for research appear appropriate given the limitations of the evidence. Authors' objectives To determine the effects of isosorbide mononitrate alone or in combination with either beta-blockers or endoscopic therapy

DARE.2010

5. The cost-effectiveness of outpatient (at home) cervical ripening with isosorbide mononitrate prior to induction of labour

The cost-effectiveness of outpatient (at home) cervical ripening with isosorbide mononitrate prior to induction of labour 19485990 2009 07 23 2009 09 14 2016 11 25 1471-0528 116 9 2009 Aug BJOG : an international journal of obstetrics and gynaecology BJOG The cost-effectiveness of outpatient (at home) cervical ripening with isosorbide mononitrate prior to induction of labour. 1196-203 10.1111/j.1471-0528.2009.02236.x To assess the cost-effectiveness of outpatient (at home) cervical ripening (...) with isosorbide mononitrate (IMN) prior to induction of labour. Economic evaluation was conducted alongside a randomised placebo controlled trial (the IMOP trial). Large UK maternity hospital. A total of 350 nulliparous women with a singleton pregnancy, cephalic presentation > or = 37 weeks gestation, requiring cervical ripening prior to induction of labour. Isosorbide mononitrate (n = 177) or placebo (n = 173) self-administered vaginally at home at 48, 32 and 16 hours prior to the scheduled time of admission

EvidenceUpdates2009

6. The cost-effectiveness of outpatient (at home) cervical ripening with isosorbide mononitrate prior to induction of labour

The cost-effectiveness of outpatient (at home) cervical ripening with isosorbide mononitrate prior to induction of labour The cost-effectiveness of outpatient (at home) cervical ripening with isosorbide mononitrate prior to induction of labour The cost-effectiveness of outpatient (at home) cervical ripening with isosorbide mononitrate prior to induction of labour Eddama O, Petrou S, Schroeder L, Bollapragada SS, Mackenzie F, Norrie J, Reid M, Norman JE Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of out-patient (at home) cervical ripening with isosorbide mononitrate, prior to the induction of labour, in comparison with no intervention in nulliparous women with a singleton pregnancy

NHS Economic Evaluation Database.2009

7. Efficacy of beta-adrenergic blocker plus 5-isosorbide mononitrate and endoscopic band ligation for prophylaxis of esophageal variceal rebleeding: a meta-analysis

Efficacy of beta-adrenergic blocker plus 5-isosorbide mononitrate and endoscopic band ligation for prophylaxis of esophageal variceal rebleeding: a meta-analysis Efficacy of beta-adrenergic blocker plus 5-isosorbide mononitrate and endoscopic band ligation for prophylaxis of esophageal variceal rebleeding: a meta-analysis Efficacy of beta-adrenergic blocker plus 5-isosorbide mononitrate and endoscopic band ligation for prophylaxis of esophageal variceal rebleeding: a meta-analysis Ding SH, Liu (...) J, Wang JP CRD summary The authors concluded that beta-adrenergic blocker plus 5-isosorbide mononitrate was as effective as endoscopic band ligation for the prophylaxis of oesophageal variceal re-bleeding. Evidence appeared to support the authors’ conclusions, but limitations in review methods and analyses based on findings of no significant difference from a few trials weaken the strength of this evidence. Authors' objectives To compare the efficacy and safety of beta-adrenergic blocker plus 5

DARE.2009

8. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding.

Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. 11547718 2001 08 15 2001 09 13 2016 11 24 0028-4793 345 9 2001 Aug 30 The New England journal of medicine N. Engl. J. Med. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. 647-55 After an episode of acute bleeding from esophageal varices, patients are at high risk for recurrent (...) bleeding and death. We compared two treatments to prevent recurrent bleeding--endoscopic ligation and combined medical therapy with nadolol and isosorbide mononitrate. We randomly assigned 144 patients with cirrhosis who were hospitalized with esophageal variceal bleeding to receive treatment with endoscopic ligation (72 patients) or the combined medical therapy (72 patients). Sessions of ligation were repeated every two to three weeks until the varices were eradicated. The initial dose of nadolol

NEJM2001

9. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP)

Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP) 8973428 1997 01 15 1997 01 15 2016 11 24 0140-6736 348 9043 1996 Dec 21-28 Lancet (London, England) Lancet Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP) 1677-81 The risk of having a first (...) cirrhosis-associated variceal bleed is lowered by about 50% by beta-blockers. Use of beta-blockers is currently recommended for patients with cirrhosis and oesophageal varices that are at risk of bleeding. We aimed to test the effectiveness of isosorbide mononitrate as an adjunct to the beta-blocker nadolol in the prophylaxis of first variceal bleeding in these patients. We did a randomised multicentre study to compare the non-selective beta-blocker, nadolol, with nadolol plus isosorbide mononitrate

Lancet1997

10. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding.

Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. 8628357 1996 06 27 1996 06 27 2016 11 23 0028-4793 334 25 1996 Jun 20 The New England journal of medicine N. Engl. J. Med. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. 1624-9 Patients who have bleeding from esophageal varices are at high risk for rebleeding and death. We compared the efficacy and safety of endoscopic (...) sclerotherapy with the efficacy and safety of nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. Eighty-six hospitalized patients with cirrhosis and bleeding from esophageal varices diagnosed by endoscopy were randomly assigned to treatment with repeated sclerotherapy (43 patients) or nadolol plus isosorbide-5-mononitrate (43 patients). The primary outcomes were rebleeding, death, and complications. The hepatic venous pressure gradient was measured at base line and after three

NEJM1996

11. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina.

Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. 1681355 1991 11 21 1991 11 21 2016 11 23 0140-6736 338 8774 1991 Oct 26 Lancet (London, England) Lancet Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. 1036-9 Many patients with angina pectoris whose symptoms are not completely controlled by beta-blockers are treated with several types of drugs, but it is not clear whether addition of a calcium (...) -channel antagonist and/or a nitrate confers any advantage over beta-blockade alone. 18 patients receiving atenolol for stable angina pectoris completed a double-blind, randomised, crossover trial of atenolol treatment plus placebo, isosorbide mononitrate, nifedipine, and mononitrate and nifedipine (triple therapy). The patients were assessed subjectively and by treadmill exercise testing and 24 h ambulatory electrocardiographic recordings at the end of each 4-week treatment period. There were

Lancet1991